Jennewein Biotechnologie GmbH announces that it has acquired the former facilities of Arthus Mineralspring Company in Bad Hönningen (Rhineland-Palatine) in order to expand the production of human milk oligosaccharides (HMOs). "We have been searching for some time for a suitable location to establish an integrated HMO fermentation and recovery plant close to our current facility in Rheinbreitbach," states Dr. Stefan Jennewein (CEO and co-founder, Jennewein Biotechnologie). "With the expansion of our HMO portfolio, and the development of our HMO Mix product, we need at least five new fermentation and recovery lines." Benedikt Engels (Chief Operation Officer, Jennewein Biotechnologie) adds "With the new plant, we will be able to produce additional HMOs, expanding our current portfolio of two products (2?-fucosyllactose and lacto-N-neotetraose) to include five more (3?-fucosyllactose, difucosyllactose, lacto-N-tetraose, 6?-sialyllactose and 3?-sialyllactose)." The new integrated facility will combine fermentation and recovery, and will yield spray-dried HMO products. Jennewein Biotechnologie plans to build separate production lines for the manufacture for each of the new HMO products. "With fermenters of more than 200m3 each, the new plant will become one of the largest fermentation facilities in central Europe," adds Stephan Michel (Chief Financial Officer, Jennewein Biotechnologie).